First trial data on setmelanotide for PWS obesity expected this year
Early findings from a Phase 2 clinical trial testing Rhythm Pharmaceuticals’ setmelanotide in children and adults with obesity due to Prader-Willi syndrome (PWS) are expected this year. That’s according to an update from Rhythm, which announced in a company press release that it plans to “disclose preliminary…